Last Updated: November 8, 2026

Chiesi Company Profile

« Back to Dashboard

What is the competitive landscape for CHIESI

CHIESI has fifteen approved drugs.

There are fifty-three US patents protecting CHIESI drugs.

Summary for Chiesi

US Patents:	53
Tradenames:	16
Ingredients:	10
NDAs:	15
Patent Litigation for Chiesi:	See patent lawsuits for Chiesi

Drugs and US Patents for Chiesi

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-006	Apr 23, 2015		DISCN	Yes	No	7,932,268	⤷ Start Trial				⤷ Start Trial
Chiesi	CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER	nicardipine hydrochloride	INJECTABLE;INTRAVENOUS	019734-005	Nov 7, 2008		DISCN	Yes	No	9,364,564	⤷ Start Trial	Y			⤷ Start Trial
Chiesi	MYCAPSSA	octreotide acetate	CAPSULE, DELAYED RELEASE;ORAL	208232-001	Jun 26, 2020		RX	Yes	Yes	11,969,471	⤷ Start Trial	Y			⤷ Start Trial
Chiesi	MYCAPSSA	octreotide acetate	CAPSULE, DELAYED RELEASE;ORAL	208232-001	Jun 26, 2020		RX	Yes	Yes	8,535,695	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Chiesi

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-006	Apr 23, 2015	8,618,135	⤷ Start Trial
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-001	Dec 21, 2012	5,712,279	⤷ Start Trial
Chiesi	BETHKIS	tobramycin	SOLUTION;INHALATION	201820-001	Oct 12, 2012	7,939,502	⤷ Start Trial
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-003	Dec 21, 2012	9,861,622	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for CHIESI drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Injection	2.5 mg/mL, 10 mL Ampoules	➤ Subscribe	2006-12-27
➤ Subscribe	Inhalation Solution	300 mg/4 mL	➤ Subscribe	2017-08-31
➤ Subscribe	Injection	0.1 mg/mL, 200 mL and0.2mg/mL, 200 mL	➤ Subscribe	2013-06-20
➤ Subscribe	Tablets	500 mg	➤ Subscribe	2016-01-29

International Patents for Chiesi Drugs

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Australia	2021316011	⤷ Start Trial
China	101484136	⤷ Start Trial
European Patent Office	3861986	⤷ Start Trial
South Korea	102440847	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for Chiesi Drugs

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2515855	122018000007	Germany	⤷ Start Trial	PRODUCT NAME: KOMBINATION VON GLYCOPYRRONIUMBROMID, FORMOTEROL ODER EINEM SALZ DAVON UND BECLOMETASONDIPROPIONAT; REGISTRATION NO/DATE: EU/1/17/1208 20170717
1725234	CR 2014 00002	Denmark	⤷ Start Trial	PRODUCT NAME: LOMITAPID ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF ELLER PIPERIDIN N-OXIDET DERAF, HERUNDER LOMITAPIDMESYLAT; REG. NO/DATE: EU/1/13/851/001-003 20130805
1280520	14/2015	Austria	⤷ Start Trial	PRODUCT NAME: TOBRAMYCIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/10/652/001-003 20110720
1758555	353 5017-2016	Slovakia	⤷ Start Trial	PRODUCT NAME: BETULIN; REGISTRATION NO/DATE: EU/1/15/1069/001 20160118
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Chiesi

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.